secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001701541-25-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M
--------------------------------------------------------------------------------

- Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.
- Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.
- Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.
- Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/0001701541-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/bdtx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001701541-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer